Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study

• Main Authors: Maud Velev (Author), Alicja Puszkiel (Author), Benoit Blanchet (Author), Sixtine de Percin (Author), Nicolas Delanoy (Author), Jacques Medioni (Author), Claire Gervais (Author), David Balakirouchenane (Author), Nihel Khoudour (Author), Patricia Pautier (Author), Alexandra Leary (Author), Zahra Ajgal (Author), Laure Hirsch (Author), François Goldwasser (Author), Jerome Alexandre (Author), Guillaume Beinse (Author)
• Format: Book
• Published: MDPI AG, 2021-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Factors associated with olaparib toxicity remain unknown in ovarian cancer patients. The large inter-individual variability in olaparib pharmacokinetics could contribute to the onset of early significant adverse events (SAE). We aimed to retrospectively analyze the pharmacokinetic/pharmacodynamic re...